 |
SV Life Sciences Fund II (SVLSFII)SVLSF II closed in 1999 with total commitments of $280 million (plus $30 million of co-investments committed by partners and individuals affiliated with SVLS). As at 31 December 2006, SVLSF II had invested $315 million (including re-investment) in 36 portfolio companies. To go to individual portfolio companies websites please click
on company logo. 
AcuFocus: USFirst investment: 2001 - Seed Implantable contact lens. 
Aderis Pharmaceuticals: USFirst investment: 2001 - Expansion - Exited Cardiovascular, renal and neurological disease focused therapeutics focused upon making a significant difference to people living with cardiovascular, renal and neurological diseases. 
Affibody: SwedenFirst investment: 2001 - Early Stage Molecular imaging and targets therapeutics. 
AllianceCare At Home: USFirst investment: 2000 - Start Up Personal in-home care. Formerly known as Sunrise at Home Assisted Living. 
Argonaut Technologies: USFirst investment: 1999 - Expansion - Exited Chemistry instrumentation for accelerated synthesis of novel organic molecules. Bought by Biotage after our exit. 
Auxilium Pharmaceuticals: USFirst investment: 2001 - Early Stage Male Hormone Replacement Therapy. 
Cadent Technologies: USFirst investment: 2000 - Early Stage Provides 3D digital information services that replace the use of physical models in denistry. 
Cardiac Support Systems: USFirst investment: 2000 - Seed - Exited This was an innovation factory company. 
CardioFocus: USFirst investment: 1999 - Early Stage Laser based ablation devices. 
Cellzome : GermanyFirst investment: 2001 - Start Up Proteomics technology for target and lead identification, and a drug discovery program in Alzheimer's Disease. 
Cerebral Vascular Applications: USFirst investment: 2000 - Seed Minimally invasive atrial fibrillation devices. Funded through the innovation factory 
Cognis: LuxembourgFirst investment: 2001 - Buy Out Speciality chemicals. Products and solutions for personal care, home care and modern nutrition. 
Confluent Surgical: USFirst investment: 1999 - Early Stage Biomaterials for adhesion prevention and vascular embolics. Easychem: US First investment: 2000 - Seed - Exited B2B chemical e-commerce electronic marketplace. 
eMed Technologies: USFirst investment: 2000 - Expansion - Exited Delivery of medical images over the internet. Expand Sante: France First investment: 2000 - Seed - Exited French pharmaceutical contract sales organisation. 
Eyetech Pharmaceuticals: USFirst investment: 2000 - Early Stage - Exited Bought by OSI Pharmaceuticals after our exit. Opthalmolological drug development. 
IHG Holdings: USFirst investment: 2001 - Buy Out Preferred provider organization.(Formerly known as Interplan). 
Ingenium: GermanyFirst investment: 2000 - Early Stage Functional genomics and drug development. 
Insulet: USFirst investment SVLSF II: 2001 - Start Up First investment SVLSF III: 2004 - Late Stage Disposable insulin infusion devices for diabetes. 
KuDOS Pharmaceuticals: UKFirst investment: 1999 - Start Up - Exited Oncology drug development. 
Liposonix: USFirst investment SVLSF II: 2001 - Seed First investment SVLSF III: 2003 - Seed Focused ultrasound alternative to liposuction.. Funded through the innovation factory. 
Lorantis Holdings: UKFirst investment SVLSF II: 2000 - Start Up First investment SVLSF III: 2003 - Early Stage Immunology based drugs. 
MDeverywhere: USFirst investment: 2001 - Early Stage Physician charge capture software. 
Metris Therapeutics: UKinvestment SVLSF I: 1998 - Start Up investment SVLSF II: 2000 - Start Up Treatment of gynaecological disorders. 
Orchid Chemicals and Pharmaceuticals: IndiaPrivate investment in Public Equity First investment: 1999 - Expansion - Exited Manufacture of bulk generic pharmaceuticals. 
Oxagen: UKFirst investment: 2000 - Expansion Clinical genomics. 
Phase Forward: USFirst investment: 1999 - Expansion Web-based information technology for clinical trials management. 
Physicians Dialysis: USFirst investment: 2001 - Buy Out - Exited Consolidator of renal dialysis centers (Purchased by DaVita). 
Quantum Dot: USFirst investment: 2000 - Early Stage - Exited Nanocrystal biological reagents. 
Quickstudy Radiology: USFirst investment: 2000 - Start Up Radiology and web-based technology service company. 
Solexa: UKFirst investment: 2001 - Start Up Ultra high throughput DNA sequencing. 
Third Wave Technologies: USFirst investment: 1999 - Expansion - Exited Products for analysing genetic variations 
Trine Pharmaceuticals: USFirst investment: 2001 - Expansion Anti-infective drug discovery. (Formerly known as Essential Therapeutics 'ETRX') 
Versicor: USFirst investment: 1999 - Expansion - Exited Drug development for infectious diseases (Changed name to Vicurion Pharmaceuticals in 2003) 
|
